Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease - A randomized, placebo-controlled study

American Heart Journal

Volumn 151, Issue 1, 2006, Pages 139.e1-139.e7

  Alber, Hannes Franz ^a   Frick, Matthias ^a   Suessenbacher, Alois ^a   Doerler, Jakob ^a   Schirmer, Michael ^a   Stocker, Eva Maria ^a   Dichtl, Wolfgang ^a   Pachinger, Otmar ^a   Weidinger, Franz ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CD4 ANTIGEN; CD40 LIGAND; CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; PLACEBO;

ADULT; ANGIOCARDIOGRAPHY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HYPERCHOLESTEROLEMIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME;

EID: 29144493384     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2005.10.006     Document Type: Article

References (39)

1. R. Ross Atherosclerosis-an inflammatory disease N Engl J Med 340 1999 115 126
2. F. Mach, U. Schonbeck, and P. Libby CD40 signaling in vascular cells: a key role in atherosclerosis? Atherosclerosis 137 Suppl 1998 S89 S95
3. G. Liuzzo, S.L. Kopecky, and R.L. Frye Perturbation of the T-cell repertoire in patients with unstable angina Circulation 100 1999 2135 2139
4. P. Andre, L. Nannizzi-Alaimo, and S.K. Prasad Platelet-derived CD40L: the switch-hitting player of cardiovascular disease Circulation 106 2002 896 899
5. P. Aukrust, F. Muller, and T. Ueland Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes Circulation 100 1999 614 620
6. G.J. Blake, R.J. Ostfeld, and E.K. Yucel Soluble CD40 ligand levels indicate lipid accumulation in carotid atheroma: an in vivo study with high-resolution MRI Arterioscler Thromb Vasc Biol 23 2003 e11 e14
7. N. Varo, J.A. de Lemos, and P. Libby Soluble CD40L: risk prediction after acute coronary syndromes Circulation 108 2003 1049 1052
8. C. Heeschen, S. Dimmeler, and C.W. Hamm Soluble CD40 ligand in acute coronary syndromes N Engl J Med 348 2003 1104 1111
9. U. Schonbeck, and P. Libby Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 109 2004 II18 II26
10. F. Mach, U. Schonbeck, and G.K. Sukhova Reduction of atherosclerosis in mice by inhibition of CD40 signalling Nature 394 1998 200 203
11. A.G. Semb, S. van Wissen, and T. Ueland Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy J Am Coll Cardiol 41 2003 275 279
12. S. Kinlay, G.G. Schwartz, and A.G. Olsson Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study Circulation 110 2004 386 391
13. L.J. Picker, M.K. Singh, and Z. Zdraveski Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry Blood 86 1995 1408 1419
14. J.J. Goronzy, E.L. Matteson, and J.W. Fulbright Prognostic markers of radiographic progression in early rheumatoid arthritis Arthritis Rheum 50 2004 43 54
15. J.J. Goronzy, and C.M. Weyand T-cell regulation in rheumatoid arthritis Curr Opin Rheumatol 16 2004 212 217
16. - T-cells in patients with small abdominal aortic aneurysms Arterioscler Thromb Vasc Biol 25 2005 1347 1352
17. - T cells in ankylosing spondylitis Arthritis Res Ther 5 2003 R292 R300
18. M. Schirmer, C. Goldberger, and R. Wurzner Circulating cytotoxic CD8(+) CD28(-) T cells in ankylosing spondylitis Arthritis Res 4 2002 71 76
19. P.W. Wilson, R.B. D'Agostino, and D. Levy Prediction of coronary heart disease using risk factor categories Circulation 97 1998 1837 1847
20. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V) Arch Intern Med 153 1993 154 183
21. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
22. U. Schonbeck, N. Gerdes, and N. Varo Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells Circulation 106 2002 2888 2893
23. E. Ascer, M.C. Bertolami, and M.L. Venturinelli Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients Atherosclerosis 177 2004 161 166
24. H. Soejima, A. Irie, and S. Miyamoto Preference toward a T-helper type 1 response in patients with coronary spastic angina Circulation 107 2003 2196 2200
25. R.S. Rosenson, and W. Koenig Utility of inflammatory markers in the management of coronary artery disease Am J Cardiol 92 2003 10i 18i
26. L. Jonasson, C. Linderfalk, and J. Olsson Systemic T-cell activation in stable angina pectoris Am J Cardiol 89 2002 754 756
27. C.J. Vaughan, and A.M. Gotto Jr Update on statins: 2003 Circulation 110 2004 886 892
28. + T cells before and after percutaneous coronary intervention and the effect of statin therapy in patients with stable angina pectoris Am J Cardiol 93 2004 1547 1549
29. B. Kwak, F. Mulhaupt, and S. Myit Statins as a newly recognized type of immunomodulator Nat Med 6 2000 1399 1402
30. U. Schonbeck, F. Mach, and P. Libby CD154 (CD40 ligand) Int J Biochem Cell Biol 32 2000 687 693
31. F. Mach, U. Schonbeck, and G.K. Sukhova Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis Proc Natl Acad Sci U S A 94 1997 1931 1936
32. V. Henn, J.R. Slupsky, and M. Grafe CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells Nature 391 1998 591 594
33. U. Schonbeck, G.K. Sukhova, and K. Shimizu Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice Proc Natl Acad Sci U S A 97 2000 7458 7463
34. T.D. Wang, W.J. Chen, and J.W. Lin Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles Atherosclerosis 170 2003 315 323
35. Y. Fan, Y. Ge, and H. Zhu Characterization and application of two novel monoclonal antibodies against CD40L: epitope and functional studies on cell membrane CD40L and studies on the origin of soluble serum CD40L Tissue Antigens 64 2004 257 263
36. E.R. Ahn, G. Lander, and W. Jy Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk Thromb Res 114 2004 143 148
37. F. Cipollone, A. Mezzetti, and E. Porreca Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy Circulation 106 2002 399 402
38. V. Sanguigni, P. Pignatelli, and L. Lenti Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients Circulation 111 2005 412 419
39. J.C. LaRosa, S.M. Grundy, and D.D. Waters Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435